# Phase 4 Renal Insufficiency trials recruiting: 45 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 45 trials in phase 4 for Renal Insufficiency that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 4 Renal Insufficiency trials: 45 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-4/renal-insufficiency

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 45
- Recruiting or not yet: 45
- Read on: November 19, 2026

## Trials

The 25 newest of 45, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 28, 2026 | NCT07900438 | A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in... | Novo Nordisk A/S | Phase 4 | Recruiting | Cardiovascular Risk, Chronic Kidney Disease | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900438) |
| October 5, 2026 | NCT07858331 | Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Obesity, Chronic Kidney Disease, Chronic Renal Disease, CKD | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858331) |
| September 10, 2026 | NCT07811427 | Heart-Kidney-Diabetes Multidisciplinary Care MOdels for CardiovascuLar Health In Patients With Chronic Kidney DiSease and Diabetes: A... | Baim Institute for Clinical Research | Phase 4 | Not yet recruiting | Chronic Kidney Disease, Type II Diabetes | 570 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811427) |
| August 3, 2026 | NCT07741292 | Niaoduqing Granules in Older Adults With Impaired Kidney Function | Huashan Hospital | Phase 4 | Recruiting | Chronic Kidney Disease | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741292) |
| July 15, 2026 | NCT07704190 | Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease | Peking University Third Hospital | Phase 4 | Not yet recruiting | Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, Coronary Artery... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704190) |
| June 25, 2026 | NCT07667517 | Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease | First Affiliated Hospital of Zhejiang University | Phase 4 | Not yet recruiting | Albuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Diseases | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667517) |
| April 17, 2026 | NCT07537088 | Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic... | First Affiliated Hospital of Wannan Medical College | Phase 4 | Not yet recruiting | T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | 468 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07537088) |
| April 14, 2026 | NCT07527390 | CANagliflozin In DIALysis Patients | University Medical Center Groningen | Phase 4 | Not yet recruiting | Dialysis, Chronic Kidney Disease (Stages 4 and 5) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527390) |
| April 13, 2026 | NCT07523867 | Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | Phase 4 | Not yet recruiting | Heart Failure, Diabetic Kidney Disease, Hyperkalemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523867) |
| February 12, 2026 | NCT07405216 | Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease | Centenario Hospital Miguel Hidalgo | Phase 4 | Recruiting | Chronic Kidney Disease (Mild to Moderate), Albuminuria, Adolescent, Sodium Glucose Co-Transporter 2 Inhibitors | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07405216) |
| February 2, 2026 | NCT07380113 | Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP | Zhujiang Hospital | Phase 4 | Recruiting | Pruritus Chronic, Kidney Diseases, Chronic, Renal Insufficiency, Chronic, Uremia; Chronic, Pruritus Due to Systemic... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07380113) |
| January 16, 2026 | NCT07345689 | A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 4 | Not yet recruiting | Hepatic Insufficiency, Renal Insufficiency, Elderly | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07345689) |
| December 2, 2025 | NCT07259512 | Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure | Sponsor not shown (see the record) | Phase 4 | Recruiting | Chronic Kidney Disease, Heart Failure With Reduced Ejection Fraction (HFrEF) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07259512) |
| November 20, 2025 | NCT07239570 | A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease | Sponsor not shown (see the record) | Phase 4 | Recruiting | Chronic Kidney Disease(CKD) | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07239570) |
| November 19, 2025 | NCT07235891 | Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | Alexandria University | Phase 4 | Not yet recruiting | Retinal Nerve Fiber Layer Thickness, Chronic Kidney Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07235891) |
| September 23, 2025 | NCT07187713 | ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases | Ace Cells Lab Limited | Phase 4 | Recruiting | Hypertensive Nephropathy, Auto Immune Disorders, Chronic Kidney Disease, Chronc Kidney Disease Stage 5, Chronic Kidney... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07187713) |
| September 8, 2025 | NCT07160452 | Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia | Shaikh Zayed Hospital, Lahore | Phase 4 | Not yet recruiting | Anemia, Kidney Failure, End-Stage Renal Disease, Renal Dialysis | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07160452) |
| September 4, 2025 | NCT07155694 | Role of Finerenone in African American Veterans With Diabetic Kidney Disease | Washington D.C. Veterans Affairs Medical Center | Phase 4 | Not yet recruiting | Diabetic Kidney Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07155694) |
| August 12, 2025 | NCT07116928 | Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 4 | Not yet recruiting | T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | 1,244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07116928) |
| July 20, 2025 | NCT07074418 | Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 | Centre Hospitalier Universitaire de Nice | Phase 4 | Recruiting | Chronic Kidney Diseases | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07074418) |
| June 22, 2025 | NCT07030894 | Nefecon and Ambrisentan in IgA Nephropathy | The First Hospital of Jilin University | Phase 4 | Recruiting | IgA Nephropathy, Chronic Kidney Disease, Proteinuria | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07030894) |
| June 18, 2025 | NCT07027774 | Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective... | First Affiliated Hospital of Wannan Medical College | Phase 4 | Not yet recruiting | Chronic Kidney Disease Stage 4 | 429 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07027774) |
| June 18, 2025 | NCT07026539 | Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | University of Aarhus | Phase 4 | Recruiting | Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Cardiovascular Diseases | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07026539) |
| June 13, 2025 | NCT07020559 | Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial | Peking University Third Hospital | Phase 4 | Not yet recruiting | Diabetic Wounds, Platelet Rich Plasma, Allogeneic Blood Transfusions, Renal Dysfunction | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020559) |
| June 12, 2025 | NCT07017270 | Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis | Unity Health Toronto | Phase 4 | Recruiting | Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07017270) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| First Affiliated Hospital of Wannan Medical College | 2 |
| University Medical Center Groningen | 2 |
| Peking University Third Hospital | 2 |
| Washington D.C. Veterans Affairs Medical Center | 2 |
| Tanta University | 2 |
| Ace Cells Lab Limited | 1 |
| Instituto de Investigación Hospital Universitario La Paz | 1 |
| Hospital Universitari Vall d'Hebron Research Institute | 1 |
| Shanghai Zhongshan Hospital | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Centenario Hospital Miguel Hidalgo | 1 |
| [Xuanzhu Biopharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/xuanzhu-biopharmaceutical-co-ltd) | 1 |
| Alexandria University | 1 |
| Herlev and Gentofte Hospital | 1 |
| Hospital Sirio-Libanes | 1 |
| Unity Health Toronto | 1 |
| University of Alberta | 1 |
| Chinese University of Hong Kong | 1 |
| Huashan Hospital | 1 |
| University Hospital Tuebingen | 1 |
| Christian Medical College, Vellore, India | 1 |
| University of Colorado, Denver | 1 |
| The First Hospital of Jilin University | 1 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 1 |
| University of Aarhus | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 9 |
| Egypt | 4 |
| Canada | 4 |
| United States | 4 |
| Denmark | 4 |
| Spain | 3 |
| Germany | 3 |
| Netherlands | 2 |
| India | 2 |
| Mexico | 1 |
| Indonesia | 1 |
| Brazil | 1 |
| Hong Kong | 1 |
| Romania | 1 |
| Sweden | 1 |
| France | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hospitals in the United States](https://specstream.ai/data/businesses/hospitals/united-states)
- [Poke restaurants in the United States](https://specstream.ai/data/businesses/poke-restaurants/united-states)
- [West African restaurants in the United States](https://specstream.ai/data/businesses/west-african-restaurants/united-states)
- [Computer hardware companies in the United States](https://specstream.ai/data/businesses/computer-hardware-companies/united-states)
- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
- [Private equity firms in the United States](https://specstream.ai/data/businesses/private-equity-firms/united-states)
